The 340B requirement has long been a bone of contention ... Last year, for example, a federal appeals court sided with Sanofi, AstraZeneca, and Novo Nordisk in a dispute claiming that recipients ...

The largest life sciences association in the state recognized those driving discovery during its 32nd annual dinner meeting ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sanofi and Johnson & Johnson are ending a Phase 3 study of an experimental E. coli vaccine after it ...

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks all but defunct after the two partners halted a phase 3 trial.

Sanofi and J&J discontinued E.mbrace phase 3 study after the vaccine showed insufficient efficacy in preventing invasive E. coli disease. Sanofi recorded a $250M impairment charge, lowering Q4 ...

Sanofi SA (NASDAQ:SNY) and Johnson & Johnson (NYSE:JNJ) have discontinued the E.mbrace phase 3 study evaluating a vaccine candidate for extraintestinal pathogenic E. coli. The E.mbrace study is a ...

Sanofi said it would discontinue its phase 3 clinical trial for an E. Coli vaccine after a review by an independent data monitoring committee. The French pharma company said the scheduled review ...

The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top ...

A new report from industry trade group the Pharmaceutical Research and Manufacturers of America (PhRMA) has shed a new light ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sanofi (SNYNF – Research Report) and Fate Therapeutics (FATE – Research Report). Leverage the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...